SCHEMBL16631442

SCHEMBL16631442

O=c1ccn2cc([C@@H]3O[C@H](CO)C(O)[C@@H]3O)c(=O)nc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 1/20 0.46
SLC28A2 O43868 1/20 0.46
SLC29A1 Q99808 1/20 0.46
SLC28A3 Q9HAS3 1/20 0.46
PYGL P06737 3/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GMNN O75496 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
STAT6 P42226 1/20 0.39
HIF1A Q16665 1/20 0.39
PNP P00491 1/20 0.38
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631328 0.89 SLC28A1 (0.45) SLC28A1SLC28A2SLC29A1SLC28A3PYGL
SCHEMBL16631648 0.81 LMNA (0.40) LMNAMAPTKDM4EGMNNBLM
SCHEMBL16631489 0.81 KDM4E (0.38) LMNAMAPTKDM4EGMNNBLM
SCHEMBL18080250 0.80 P2RY2 (0.52)
SCHEMBL16631484 0.78 PNP (0.39) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL16631485 0.78 KDM4E (0.40) SLC28A1SLC28A2SLC29A1SLC28A3PYGL
SCHEMBL16631441 0.73 PYGM (0.38) LMNAMAPTKDM4EGMNNBLM
SCHEMBL16631644 0.73 PNP (0.36) PYGLLMNAMAPTKDM4EGMNN
SCHEMBL16631702 0.72 PNP (0.35) PYGLLMNAMAPTKDM4EGMNN
SCHEMBL16631646 0.72 PNP (0.35) LMNAMAPTKDM4EGMNNBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 SLC28A1 302/4885SLC28A2 214/4885SLC29A1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.